ANNE S TUGGLE
- Type
- Physician · Allopathic & Osteopathic Physicians / Family Medicine
- Where
- MAULDIN, SC
- NPI
- 1518923531
- Received
- $95,459 in 425 records, 2019 to 2025 ($13,693 general, $81,765 research)
- As principal investigator
- $2,083,658 of research payments to others in 49 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 25 | $482 |
| 2024 | General payment | 61 | $3,332 |
| 2024 | Research payment | 2 | $43,796 |
| 2023 | General payment | 57 | $3,261 |
| 2023 | Research payment | 1 | $3,892 |
| 2022 | General payment | 50 | $1,070 |
| 2022 | Research payment | 1 | $28,932 |
| 2021 | General payment | 95 | $2,159 |
| 2020 | General payment | 80 | $1,257 |
| 2019 | General payment | 51 | $2,128 |
| 2019 | Research payment | 2 | $5,145 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 6 | $81,765 |
| Food and Beverage | 406 | $10,505 |
| Travel and Lodging | 11 | $3,111 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $70 |
| Education | 1 | $6 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-10-13 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-09-22 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-08-25 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-08-18 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-08-11 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-07-21 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-07-14 | Medtronic, Inc. | $18 | Food and Beverage | In-kind items and services | INCEPTIV Device, Spinal Cord Neurostimulation | 2025 | |
| 2025-06-18 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-06-16 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-06-09 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-06-04 | AstraZeneca Pharmaceuticals LP | $33 | Food and Beverage (4 payments) | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-05-20 | Vanda Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2025 | |
| 2025-05-20 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-05-08 | AstraZeneca Pharmaceuticals LP | $87 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-05-04 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-28 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-31 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-03-26 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-03-17 | Merck Sharp & Dohme LLC | $13 | Food and Beverage | In-kind items and services | GARDASIL 9 Biological, VACCINE | 2025 | |
| 2025-02-24 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-02-10 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-02-05 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-01-20 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-01-13 | Phathom Pharmaceuticals, Inc. | $13 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-01-06 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2024-12-16 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2024 | |
| 2024-12-04 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-11-19 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-11-13 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-11-12 | Daiichi Sankyo Inc. | $125 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2024 | |
| 2024-11-11 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-11-04 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-10-24 | AstraZeneca Pharmaceuticals LP | $118 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-10-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | SYNJARDY Drug, DIABETES | 2024 | |
| 2024-10-09 | Abbott Laboratories | $18 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-10-07 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $34,509 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 | |
| 2024-09-23 | Eli Lilly and Company | $9,287 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 | |
| 2024-09-09 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-09-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-09-04 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-08-29 | AstraZeneca Pharmaceuticals LP | $90 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-08-26 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-08-21 | Eli Lilly and Company | $107 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-08-21 | Eli Lilly and Company | $7 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-08-19 | PFIZER INC. | $9 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2024 | |
| 2024-08-14 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-08-12 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-07-15 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2024 | |
| 2024-07-01 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-06-24 | Daiichi Sankyo Inc. | $12 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2024 | |
| 2024-06-17 | Eli Lilly and Company | $339 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $320 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $118 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $51 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $51 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $42 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $32 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $32 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $32 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $15 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-16 | Eli Lilly and Company | $636 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-11 | Abbott Laboratories | $17 | Food and Beverage | In-kind items and services | PROCLAIM Device, Neuromodulation | 2024 | |
| 2024-06-05 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-06-03 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-05-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | TRADJENTA Drug, DIABETES | 2024 | |
| 2024-05-01 | Eisai Inc. | $24 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-04-29 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-04-15 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-04-08 | Edwards Lifesciences Corporation | $29 | Food and Beverage | In-kind items and services | Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2024 | |
| 2024-04-01 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-03-20 | Amgen Inc. | $125 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-03-14 | AstraZeneca Pharmaceuticals LP | $142 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-03-13 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-03-04 | AstraZeneca Pharmaceuticals LP | $31 | Food and Beverage (4 payments) | In-kind items and services | BREZTRI Drug, Respiratory | 2024 | |
| 2024-02-29 | PFIZER INC. | $124 | Food and Beverage | In-kind items and services | ABRYSVO Biological, VACCINES | 2024 | |
| 2024-02-19 | AstraZeneca Pharmaceuticals LP | $27 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-02-12 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-02-05 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2024 | |
| 2024-01-22 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-01-17 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-01-15 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-01-11 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-01-10 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-01-08 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-01-03 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2023-12-13 | Bayer Healthcare Pharmaceuticals Inc. | $11 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-12-04 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-27 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-11-06 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-04 | GlaxoSmithKline, LLC. | $6 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2023 | |
| 2023-10-31 | Abbott Laboratories | $21 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-10-26 | Corcept Therapeutics | $13 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-10-26 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-10-24 | GlaxoSmithKline, LLC. | $120 | Food and Beverage | In-kind items and services | AREXVY Drug, RESPIRATORY | 2023 | |
| 2023-10-18 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2023 | |
| 2023-10-05 | AstraZeneca Pharmaceuticals LP | $6 | Food and Beverage (2 payments) | In-kind items and services | BREZTRI Drug, Respiratory | 2023 | |
| 2023-09-28 | ABBVIE INC. | $122 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-09-27 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-09-25 | Bayer Healthcare Pharmaceuticals Inc. | $12 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-09-20 | Daiichi Sankyo Inc. | $96 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2023 | |
| 2023-09-19 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2023 | |
| 2023-09-14 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-09-06 | Exact Sciences Corporation | $12 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2023 | |
| 2023-08-30 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-08-30 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-08-28 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2023 | |
| 2023-08-16 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-08-07 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-08-03 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2023 | |
| 2023-07-31 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2023 | |
| 2023-07-20 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-06-14 | Exact Sciences Corporation | $14 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2023 | |
| 2023-06-07 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | AREXVY Drug, RESPIRATORY | 2023 | |
| 2023-05-31 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2023 | |
| 2023-05-22 | SANOFI-AVENTIS U.S. LLC | $15 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-05-17 | Bayer Healthcare Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-05-10 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-05-03 | AstraZeneca Pharmaceuticals LP | $134 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-04-26 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2023 | |
| 2023-04-25 | Genentech USA, Inc. | $111 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-04-25 | Genentech USA, Inc. | $14 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-04-19 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-04-18 | Abbott Laboratories | $23 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2023 | |
| 2023-04-17 | Bayer Healthcare Pharmaceuticals Inc. | $9 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-04-12 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-04-10 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-03-30 | Genentech USA, Inc. | $1 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-03-29 | Genentech USA, Inc. | $856 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-03-29 | Genentech USA, Inc. | $795 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-03-29 | Genentech USA, Inc. | $1 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-03-15 | SANOFI-AVENTIS U.S. LLC | $14 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-02-22 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-02-22 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-02-21 | ABBVIE INC. | $120 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-02-14 | Bayer Healthcare Pharmaceuticals Inc. | $3 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-02-13 | Daiichi Sankyo Inc. | $19 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2023 | |
| 2023-02-08 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-02-03 | Bayer Healthcare Pharmaceuticals Inc. | $115 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-01-26 | GlaxoSmithKline, LLC. | $121 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2023 | |
| 2023-01-25 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-01-23 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-01-10 | Eli Lilly and Company | $3,892 | Research payment | In-kind items and services | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 | |
| 2023-01-09 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2022-12-12 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-12-05 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-11-30 | SANOFI-AVENTIS U.S. LLC | $13 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2022 | |
| 2022-11-23 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-11-15 | AstraZeneca Pharmaceuticals LP | $122 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-11-14 | SANOFI-AVENTIS U.S. LLC | $15 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2022 | |
| 2022-11-09 | Bayer Healthcare Pharmaceuticals Inc. | $12 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-10-24 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-10-12 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-10-06 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2022 | |
| 2022-10-04 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2022 | |
| 2022-09-28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2022 | |
| 2022-09-21 | Janssen Pharmaceuticals, Inc | $108 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-09-19 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-09-14 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-08-22 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-08-17 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2022 | |
| 2022-08-15 | Janssen Pharmaceuticals, Inc | $26 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-08-03 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2022 | |
| 2022-08-01 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-07-28 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-07-26 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2022 | |
| 2022-07-18 | Eisai Inc. | $23 | Food and Beverage | Cash or cash equivalent | Dayvigo Drug, Neurology | 2022 | |
| 2022-07-11 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-05-24 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2022 | |
| 2022-05-18 | Daiichi Sankyo Inc. | $15 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2022 | |
| 2022-05-16 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-05-11 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-05-10 | GlaxoSmithKline, LLC. | $110 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2022 | |
| 2022-05-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-05-02 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-04-27 | Bayer Healthcare Pharmaceuticals Inc. | $11 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-04-25 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2022 | |
| 2022-04-20 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-04-18 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-04-13 | Esperion Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2022 | |
| 2022-04-12 | Janssen Pharmaceuticals, Inc | $18 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-04-04 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2022 | |
| 2022-03-28 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2022 | |
| 2022-03-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | TRADJENTA Drug, DIABETES | 2022 | |
| 2022-03-16 | Eisai Inc. | $14 | Food and Beverage | Cash or cash equivalent | Dayvigo Drug, Neurology | 2022 | |
| 2022-03-02 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-02-28 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-02-16 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-02-09 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-02-08 | Eli Lilly and Company | $28,932 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-01-31 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage (2 payments) | In-kind items and services | BREZTRI Drug, Respiratory | 2022 | |
| 2022-01-26 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-01-24 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2022 | |
| 2022-01-10 | Janssen Pharmaceuticals, Inc | $17 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-01-06 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2022 | |
| 2021-12-20 | Bayer Healthcare Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2021 | |
| 2021-12-20 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-12-13 | Daiichi Sankyo Inc. | $117 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2021 |
The latest 200 records of 425.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-03 | AstraZeneca Pharmaceuticals LP | CARE ACCESS RESEARCH | $20,650 | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major | 2025 |
| 2025-10-10 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $1,090 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | CARE ACCESS RESEARCH | $20,650 | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Densit | 2025 |
| 2025-05-23 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $166,758 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AN | 2025 |
| 2025-04-21 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $162 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2025 |
| 2025-04-16 | Genentech, Inc. | CARE ACCESS RESEARCH LLC | $2,000 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-04-16 | Genentech, Inc. | CARE ACCESS RESEARCH LLC | $1,800 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-04-16 | Genentech, Inc. | CARE ACCESS RESEARCH LLC | $500 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-04-09 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $9,934 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AN | 2025 |
| 2025-02-10 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $1,725 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-01-31 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $570 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-27 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $11,710 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2025 |
| 2025-01-21 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $34,198 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-01-07 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $183,539 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2025 |
| 2025-01-07 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $66,106 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2025 |
| 2024-12-11 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $8,896 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-11-20 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $143 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-11-13 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $801 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-10-16 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $801 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-08-14 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $1,704 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-07-26 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $1,704 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-07-19 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $950 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-06-28 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $5,529 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-06-03 | Genentech, Inc. | CARE ACCESS RESEARCH LLC | $2,200 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2024 |
| 2024-06-03 | Genentech, Inc. | CARE ACCESS RESEARCH LLC | $12,000 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2024 |
| 2024-06-03 | Genentech, Inc. | CARE ACCESS RESEARCH LLC | $1,000 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2024 |
| 2024-06-03 | Genentech, Inc. | CARE ACCESS RESEARCH LLC | $500 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2024 |
| 2024-06-03 | Genentech, Inc. | CARE ACCESS RESEARCH LLC | $1,000 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2024 |
| 2024-04-18 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $859 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 |
| 2024-03-25 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $47,761 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 |
| 2024-03-25 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $196,068 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 |
| 2024-02-21 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $50 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-02-13 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $8,978 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 |
| 2024-01-22 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $1,182 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-12 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $19,960 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-09 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $1,258 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2024-01-02 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $92,012 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2023-11-10 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $1,971 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-07-11 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $2,768 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2023-06-05 | Chiesi USA, Inc. | CARE ACCESS RESEARCH LLC | $10,500 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2023 |
| 2023-01-03 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $390,445 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2022-02-25 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $555,464 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 |
| 2022-02-01 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $24 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 |
| 2019-08-19 | Eli Lilly and Company | FAMILIES FIRST FAMILY MEDICINE PC | $9,870 | A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | 2019 |
| 2019-08-12 | Eli Lilly and Company | FAMILIES FIRST FAMILY MEDICINE PC | $1,500 | A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES A | 2019 |
| 2019-02-25 | Eli Lilly and Company | THE RESEARCH CENTER OF THE UPSTATE | $9,522 | A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES A | 2019 |
| 2019-02-05 | Eli Lilly and Company | THE RESEARCH CENTER OF THE UPSTATE | $127,660 | A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | 2019 |
| 2019-01-22 | Eli Lilly and Company | THE RESEARCH CENTER OF THE UPSTATE | $692 | A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES A | 2019 |
| 2019-01-16 | Eli Lilly and Company | THE RESEARCH CENTER OF THE UPSTATE | $46,488 | A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Mauldin, SC, county Greenville County, SC, state South Carolina; placed by its city name.
| Measure | Place (city or town) Mauldin, SC | County Greenville County, SC | State South Carolina |
|---|---|---|---|
| Population B01003 | 27,055 | 548,166 | 5,296,225 |
| Population, 2020 census P1 | 24,724 | 525,534 | 5,118,425 |
| Median age B01002 | 40.9 | 38.4 | 40.2 |
| Under 18 B01001 | 19.7% | 22.9% | 21.4% |
| 65 and over B01001 | 18.4% | 16.7% | 18.9% |
| Households B11001 | 11,656 | 220,565 | 2,117,989 |
| Foreign born B05002 | 6.9% | 8.7% | 5.8% |
| Median household income B19013 | $82,331 | $76,932 | $69,324 |
| Median family income B19113 | $98,389 | $96,425 | $86,707 |
| Per capita income B19301 | $43,015 | $43,319 | $39,236 |
| Poverty rate B17001 | 8.4% | 10.8% | 14.1% |
| Unemployment rate B23025 | 4.9% | 4.4% | 4.9% |
| Civilian labor force B23025 | 15,254 | 285,521 | 2,560,429 |
| Mean commute (minutes) B08013 | 21.1 | 23.4 | 25.6 |
| Bachelor's degree or higher B15003 | 38.7% | 41.3% | 32.1% |
| Housing units B25001 | 11,907 | 238,260 | 2,443,039 |
| Owner-occupied B25003 | 68.0% | 68.9% | 71.9% |
| Renters B25003 | 32.0% | 31.1% | 28.1% |
| Median home value B25077 | $258,500 | $299,000 | $259,000 |
| Median gross rent B25064 | $1,490 | $1,262 | $1,180 |
| White, not Hispanic B03002 | 59.3% | 65.2% | 61.9% |
| Black B03002 | 23.6% | 15.3% | 24.6% |
| Hispanic or Latino B03002 | 10.2% | 11.6% | 7.4% |
| Asian B03002 | 3.4% | 2.5% | 1.7% |
| American Indian and Alaska Native B03002 | 0.0% | 0.2% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Mauldin, SC.
Comments